Dysregulated cell division, which leads to aberrant cell proliferation, is one of the key
hallmarks of cancer. Therefore, therapeutic targets that block cell division would be effective …

The MYC family oncogene is deregulated in> 50% of human cancers, and this deregulation
is frequently associated with poor prognosis and unfavorable patient survival. Myc has a …

Sulfoximines have been largely disregarded in medicinal chemistry for a long time.
However, recently, they have risen to the apparent level of stardom on the drug discovery …

This paper describes the substances of plant and marine origin that have anticancer
properties. The chemical structure of the molecules of these substances, their properties …

Alzheimer's disease (AD) is a progressive neurodegenerative disease and accounts for
most cases of dementia. The prevalence of AD has increased in the current rapidly aging …

Nowadays, cancer is one of the deadliest diseases in the world, which has been estimated
to cause 9.9 million deaths in 2020. Conventional treatments for cancer commonly involve …

Presently, breast cancer (BC) is one of the most common malignancies diagnosed and the
leading cause of tumor-related deaths among women worldwide. Cell cycle dysregulation is …

Cyclin dependent kinases (CDKs) are serine/threonine kinases that are proposed as
promising candidate targets for cancer treatment. These proteins complexed with cyclins …

Deregulation of the cell cycle machinery, which has been linked to dysregulation of cyclin-
dependent kinases (CDKs), is a defining characteristic of cancer, eventually promoting …

Promotion of the cell cycle is a major oncogenic mechanism of the oncogene c-MYC (MYC).
MYC promotes the cell cycle by not only activating or inducing cyclins and CDKs but also …